SAM Advisors LLC Buys 1,724 Shares of Kenvue Inc. $KVUE

SAM Advisors LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 3.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 58,192 shares of the company’s stock after purchasing an additional 1,724 shares during the quarter. Kenvue comprises 0.4% of SAM Advisors LLC’s investment portfolio, making the stock its 23rd largest holding. SAM Advisors LLC’s holdings in Kenvue were worth $1,218,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. increased its stake in shares of Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock valued at $2,545,000 after acquiring an additional 4,034 shares in the last quarter. Renaissance Capital LLC increased its stake in shares of Kenvue by 8.3% in the 2nd quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after acquiring an additional 48,267 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Kenvue by 80.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after acquiring an additional 16,164 shares in the last quarter. Arlington Partners LLC bought a new stake in shares of Kenvue in the 2nd quarter valued at $2,110,000. Finally, Cornell Pochily Investment Advisors Inc. increased its stake in shares of Kenvue by 144.6% in the 2nd quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after acquiring an additional 19,609 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE opened at $15.30 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The company has a market capitalization of $29.37 billion, a price-to-earnings ratio of 20.68, a P/E/G ratio of 2.20 and a beta of 0.72. The firm’s fifty day moving average price is $18.54 and its two-hundred day moving average price is $21.04. Kenvue Inc. has a 1 year low of $14.05 and a 1 year high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.4%. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is presently 112.16%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on KVUE shares. Bank of America lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, October 8th. JPMorgan Chase & Co. decreased their price target on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Citigroup decreased their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Finally, Canaccord Genuity Group decreased their price target on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.